Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US CMS changes tack on coverage policy for weight loss surgery

This article was originally published in Clinica

Executive Summary

US Medicare is proposing to eliminate coverage of bariatric surgery for beneficiaries aged 65 and over, after concluding that the procedure is too risky for this age group. But the health plan would continue to cover the costly procedure for certain morbidly obese beneficiaries under the age of 65 undergoing one of three commonly performed procedures: open and laparoscopic Roux-en-Y gastric bypass; and laparoscopic adjustable gastric banding. The latter procedure is currently available in the US only via Inamed's LapBand device. "While the best proven 'treatment' is a nutritious diet and regular exercise - and medical treatments are also available - some beneficiaries may significantly reduce their health risks through surgery," said CMS administrator Dr Mark McClellan. The Centers for Medicare & Medicaid Services (CMS) said it decided to stop covering the weight loss surgery for the elderly, based in part on a recent study in the Journal of the American Medical Association that found that patients aged 65 and older had two- to three-fold higher death rates after weight loss surgery.

You may also be interested in...



Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel